Scientific article

Vertraglichkeit des selektiven Cyclooxygenase-2-Inhibitors Rofecoxib bei Intoleranz gegenuber nicht-steroidalen Antiphlogistika

Other titleTolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents
Published inDeutsche Medizinische Wochenschrift, vol. 126, no. 14, p. 386-388
Publication date2001

BACKGROUND AND OBJECTIVE: Pseudoallergic reactions triggered by nonsteroidal anti-inflammatory drugs (NSAIDs) are common and caused by inhibition of the enzyme cyclooxygenase-1, whereas their therapeutic effects are mediated by inhibition of cyclooxygenase-2. This study analyzed the tolerability of the selective cyclooxygenase-2-inhibitor rofecoxib in patients who encountered pseudoallergic reactions to NSAIDs. PATIENTS AND METHODS: 37 patients (12 males, 25 females, mean age 35 years [15-75 years]) with a history of pseudoallergic reactions to NSAIDs underwent standardized skin prick, scratch and patch tests along with oral placebo-controlled blinded exposure to rofecoxib (maximum single dose 12.5 mg, cumulative dose 25 mg). RESULTS: 23 patients had skin reactions, 4 times respiratory symptoms were documented, and in 10 cases cutaneous as well as respiratory symptoms were reported. Salicylic acid was identified as the most common trigger for a pseudoallergic reaction (n = 28). In 9 cases several non-steroidal antiphlogistics of different chemical groups caused symptoms. All skin tests showed negative results. Oral challenge with rofecoxib was tolerated by all 37 patients without adverse effects. CONCLUSION: Given the high incidence of pseudoallergic reactions to NSAIDs the use of selective cyclooxygenase-2-inhibitors represents a therapeutic alternative as well as a means of prevention of the described reactions.

  • Adolescent
  • Adult
  • Aged
  • *Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects
  • *Cyclooxygenase Inhibitors/administration & dosage/adverse effects
  • Drug Eruptions/diagnosis/etiology/prevention & control
  • Drug Hypersensitivity/diagnosis/*etiology/prevention & control
  • Female
  • Humans
  • *Lactones/administration & dosage/adverse effects
  • Male
  • Middle Aged
  • Placebos
  • Skin Tests
  • Sulfones
Affiliation Not a UNIGE publication
Citation (ISO format)
ZOLLNER, Thomas Matthias et al. Vertraglichkeit des selektiven Cyclooxygenase-2-Inhibitors Rofecoxib bei Intoleranz gegenuber nicht-steroidalen Antiphlogistika. In: Deutsche Medizinische Wochenschrift, 2001, vol. 126, n° 14, p. 386–388. doi: 10.1055/s-2001-12640
ISSN of the journal0012-0472

Technical informations

Creation09/20/2013 4:32:55 PM
First validation09/20/2013 4:32:55 PM
Update time03/14/2023 8:24:46 PM
Status update03/14/2023 8:24:46 PM
Last indexation01/16/2024 2:09:15 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack